کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
5997020 1578936 2014 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
Anthracycline cardiotoxicity in survivors of childhood cancer: Clinical course, protection, and treatment
ترجمه فارسی عنوان
سمیت کاتدی آنتراسیکلین در بازماندگان سرطان دوران کودکی: دوره بالینی، حفاظت و درمان
کلمات کلیدی
انتراسیکلین، دکستروزان بازماندگان سرطان دوران کودکی، اثرات متوقف قلب سمیت قلبی، سرطان دوران کودکی،
موضوعات مرتبط
علوم پزشکی و سلامت پزشکی و دندانپزشکی کاردیولوژی و پزشکی قلب و عروق
چکیده انگلیسی

Childhood cancer survivors are now living longer as a result of advancements in cancer treatment, but not without consequences. Cardiovascular disease is the leading non-cancer-related cause of morbidity and mortality in long-term survivors of childhood cancer. Cardiotoxicity associated with cancer treatment in children can be pervasive, persistent, and progressive. Serum cardiac biomarker concentrations during therapy can predict late cardiotoxicity; although there is still a need for validated cardiac monitoring guidelines. The cardioprotective strategy of continuous infusion of doxorubicin, while showing short-term benefit in adults, provides no long-term cardioprotection or improvement in event-free survival over bolus-infusion in children with a diagnosis of acute lymphoblastic leukemia. However, dexrazoxane protects the heart from the cardiotoxic effects of anthracycline treatment and does not interfere with oncologic efficacy or increase the risk of second malignancies. The emerging field of cardio-oncology emphasizes the need for collaborations between cardiologists and oncologists to find a balance between oncologic efficacy and the risks of cardiotoxicity to maximize the quality of life and survival for long-term survivors of childhood cancer.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Progress in Pediatric Cardiology - Volume 36, Issues 1–2, September 2014, Pages 11-18
نویسندگان
, , ,